ICER plans to assess the comparative clinical effectiveness and value of aducanumab (Biogen) for the treatment of Alzheimer’s disease. The FDA is expected to make a decision on aducanumab in early 2021.
Date of review: May 2021
For questions, please contact Laura Cianciolo, Program Manager, at firstname.lastname@example.org.
ASSOCIATED MEETING & MATERIALS
The CTAF will convene virtually to deliberate and vote on evidence presented in ICER's report on Alzheimer's disease.